Imago BioSciences Appoints Laurie Keating to Board of Directors
“I am pleased to welcome to Laurie to Imago’s Board of Directors as the company continues to grow, following our successful IPO in July,” said
“Imago’s advances in the potential treatment of myeloproliferative neoplasms with bomedemstat are highly promising, and I am thrilled to join the company’s Board of Directors at such an exciting time,” said
Keating currently sits on the Board of Directors for Immuneering Corporation and MassBIO, a non-profit organization dedicated to growing the biopharmaceutical industry, adding value to the healthcare system, and improving patient lives in
Forward Looking Statements
This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “may,” “will,” “should,” “expect,” “believe” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.
These statements may relate to, but are not limited to, Keating’s contributions to Imago’s Board of Directors, the results, conduct, progress and timing of Imago’s clinical trials, the regulatory approval path for bomedemstat, expectations of future operating results or financial performance, market size and growth opportunities, plans for future operations, competitive position, technological capabilities and strategic relationships, as well as assumptions relating to the foregoing. Forward looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. You should not put undue reliance on any forward looking statements. Forward looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.
Except as required by law, Imago does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Source: Imago BioSciences, Inc.